What Zymeworks Inc. does.

Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat conditions, including cancer, inflammation, and autoimmune disease. We believe our asset and royalty aggregation strategy differentiates us from other biotechnology companies because it provides us with an opportunity to optimize future milestone and royalty cash flows and selectively invest in high-quality assets while retaining the flexibility to return capital to stockholders.

Our strategy is focused on compounding long-term stockholder value through a combination of royalty growth, strategic acquisitions, and internal innovation, supported by disciplined capital allocation and a strengthened financial foundation through expected milestone payments and royalties from existing commercial partners. We pursue this strategy by discovering or acquiring and developing a diversified portfolio of preclinical or clinical healthcare assets while also evaluating strategic partnership opportunities to transfer certain costs and risks related to clinical development a nd/or commercialization to our strategic partners and secure the right to receive potential future royalty and milestone revenues. The following elements collectively support the execution of our strategy.

Revenue and profit, by fiscal year.

More on ZYME.

• Zymeworks Inc. summary
• Zymeworks Inc. financial statements
• Zymeworks Inc. key metrics
• Zymeworks Inc. health scores and style box
• Zymeworks Inc. earnings
• Zymeworks Inc. dividends
• Zymeworks Inc. valuation
• Zymeworks Inc. ownership and insiders
• Zymeworks Inc. peers

Figures from Zymeworks Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.